Why did 4588.T stock surge pre-market today?

4588.T stock rose on 20 Jan 2026 due to increased volume and renewed focus on Oncolys' clinical pipeline and diagnostics. Short-term momentum and sector flows into biotech names on JPX amplified the move; confirm catalysts before trading.

What are the valuation metrics for 4588.T stock?

4588.T stock shows EPS **-93.07**, PE **-20.88**, market cap **JPY 48,278,424,366.00**, price-to-book **28.28**, and cash per share **JPY 52.45**. These reflect development-stage valuation and high future-growth expectations.

How does Meyka AI view 4588.T stock?

Meyka AI rates 4588.T with a score out of 100: **64.00**, Grade **B**, suggestion **HOLD**. The score considers benchmarks, sector performance, growth, metrics, and analyst signals; not investment advice.

What is the short-term forecast for 4588.T stock?

Meyka AI's forecast model projects a monthly level of **JPY 1,804.01**, implying a model-based downside of **-16.98%** from the current **JPY 2,173.00**. Forecasts are model-based projections and not guarantees.

JP Stocks

4588.T Oncolys BioPharma JPX up 26.48% pre-market 20 Jan 2026: outlook

ByHuzaifa Zahoor January 20, 2026

4588.T stock leads pre-market gains on JPX after a strong intraday move, trading at JPY 2,173.00 on 20 Jan 2026, up 26.48% from the previous close. Volume is elevated at 3,744,600.00 shares versus a 50-day average of 3,145,561.00, showing real buying interest. The move outpaces the Healthcare sector and follows company and market signals that traders should weigh carefully before entering new positions.